Cargando…

Magnitude of Drug–Drug Interactions in Special Populations

Drug–drug interactions (DDIs) are one of the most frequent causes of adverse drug reactions or loss of treatment efficacy. The risk of DDIs increases with polypharmacy and is therefore of particular concern in individuals likely to present comorbidities (i.e., elderly or obese individuals). These sp...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bettonte, Sara, Berton, Mattia, Marzolini, Catia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9027396/ https://www.ncbi.nlm.nih.gov/pubmed/35456623 http://dx.doi.org/10.3390/pharmaceutics14040789

Ejemplares similares

Impact of Obesity on the Drug–Drug Interaction Between Dolutegravir and Rifampicin or Any Other Strong Inducers
por: Berton, Mattia, et al.
Publicado: (2023)

Management of Drug-Drug Interactions Between Long-Acting Cabotegravir and Rilpivirine and Comedications With Inducing Properties: A Modeling Study
por: Bettonte, Sara, et al.
Publicado: (2022)

Management of Drug Interactions with Inducers: Onset and Disappearance of Induction on Cytochrome P450 3A4 and Uridine Diphosphate Glucuronosyltransferase 1A1 Substrates
por: Bettonte, Sara, et al.
Publicado: (2023)

Physiologically Based Pharmacokinetic Modelling to Identify Physiological and Drug Parameters Driving Pharmacokinetics in Obese Individuals
por: Berton, Mattia, et al.
Publicado: (2022)

Repository Describing the Anatomical, Physiological, and Biological Changes in an Obese Population to Inform Physiologically Based Pharmacokinetic Models
por: Berton, Mattia, et al.
Publicado: (2022)

Population pharmacokinetic modelling to quantify the magnitude of drug-drug interactions between amlodipine and antiretroviral drugs
por: Courlet, Perrine, et al.
Publicado: (2021)

Analysis of Clinical Drug-Drug Interaction Data To Predict Magnitudes of Uncharacterized Interactions between Antiretroviral Drugs and Comedications
por: Stader, Felix, et al.
Publicado: (2018)

Pharmacokinetics and Drug–Drug Interactions of Long-Acting Intramuscular Cabotegravir and Rilpivirine
por: Hodge, Daryl, et al.
Publicado: (2021)

Prescribing issues in older adults living with HIV: thinking beyond drug–drug interactions with antiretroviral drugs
por: Livio, Françoise, et al.
Publicado: (2019)

Cobicistat: A case of mislabelled drug‐drug interaction risk?
por: Burger, David M., et al.
Publicado: (2020)

Drug–Drug Interactions with Antiretroviral Drugs in Pregnant Women Living with HIV: Are They Different from Non-Pregnant Individuals?
por: Bukkems, Vera E., et al.
Publicado: (2020)

Dexamethasone is a dose-dependent perpetrator of drug–drug interactions: implications for use in people living with HIV
por: Jacobs, Tom G, et al.
Publicado: (2021)

Physiologically‐Based Pharmacokinetic Modeling to Support the Clinical Management of Drug–Drug Interactions With Bictegravir
por: Stader, Felix, et al.
Publicado: (2021)

Polypharmacy, Drug–Drug Interactions, and Inappropriate Drugs: New Challenges in the Aging Population With HIV
por: Courlet, Perrine, et al.
Publicado: (2019)

COVID‐19 treatment in patients with comorbidities: Awareness of drug‐drug interactions
por: Back, David, et al.
Publicado: (2020)

Evaluating the risk of drug-drug interactions with pharmacokinetic boosters: the case of ritonavir-enhanced nirmatrelvir to prevent severe COVID-19
por: Girardin, François, et al.
Publicado: (2022)

Recommendations for the Management of Drug–Drug Interactions Between the COVID‐19 Antiviral Nirmatrelvir/Ritonavir (Paxlovid) and Comedications
por: Marzolini, Catia, et al.
Publicado: (2022)

Development of an evidence evaluation and synthesis system for drug-drug interactions, and its application to a systematic review of HIV and malaria co-infection
por: Seden, Kay, et al.
Publicado: (2017)

Influence of Drug–Drug Interactions on the Pharmacokinetics of Atorvastatin and Its Major Active Metabolite ortho-OH-Atorvastatin in Aging People Living with HIV
por: Courlet, Perrine, et al.
Publicado: (2020)

Special Issue on Drug–Membrane Interactions
por: Pinheiro, Marina
Publicado: (2021)

The challenge of HIV treatment in an era of polypharmacy
por: Back, David, et al.
Publicado: (2020)

Magnitude of drug resistant shigellosis in Nepalese patients
por: Khan, Salman, et al.
Publicado: (2013)

MULTIPLE DRUG INTERACTION ACROSS MEDICAL SPECIALIZATIONS
por: Andrade, Chittaranjan
Publicado: (1999)

Special Issue on Drug–Membrane Interactions Volume II
por: Pinheiro, Marina, et al.
Publicado: (2022)

Time of the Day and Magnitude of the Effect of a Drug on the QTc Interval
por: Täubel, J, et al.
Publicado: (2017)

Particle Nanoarchitectonics for Nanomedicine and Nanotherapeutic Drugs with Special Emphasis on Nasal Drugs and Aging
por: Aziz, Tariq, et al.
Publicado: (2023)

Drug-drug interactions with raltegravir
por: Burger, David M
Publicado: (2009)

Potential drug–drug interactions in Alzheimer patients with behavioral symptoms
por: Pasqualetti, Giuseppe, et al.
Publicado: (2015)

Why does the magnitude of genotype‐by‐environment interaction vary?
por: Saltz, Julia B., et al.
Publicado: (2018)

From Microscale to Macroscale: Nine Orders of Magnitude for a Comprehensive Modeling of Hydrogels for Controlled Drug Delivery
por: Casalini, Tommaso, et al.
Publicado: (2019)

The Influence of Pharmacogenetics on the Clinical Relevance of Pharmacokinetic Drug–Drug Interactions: Drug–Gene, Drug–Gene–Gene and Drug–Drug–Gene Interactions
por: Hahn, Martina, et al.
Publicado: (2021)

Application of Physiologically Based Pharmacokinetic Modeling to Predict Drug Exposure and Support Dosing Recommendations for Potential Drug‐Drug Interactions or in Special Populations: An Example Using Tofacitinib
por: Tse, Susanna, et al.
Publicado: (2020)

Ionic Liquids as Tools to Incorporate Pharmaceutical Ingredients into Biopolymer-Based Drug Delivery Systems
por: Berton, Paula, et al.
Publicado: (2023)

Understanding and preventing drug–drug and drug–gene interactions
por: Tannenbaum, Cara, et al.
Publicado: (2014)

Renal drug transporters and their significance in drug–drug interactions
por: Yin, Jia, et al.
Publicado: (2016)

Adverse drug reactions and interactions: first reports and special situations
Publicado: (2020)

Special topic: Emerging role of transporters in drug interaction and delivery
por: Kou, Longfa, et al.
Publicado: (2020)

The Magnitude of Candida albicans Stress-Induced Genome Instability Results from an Interaction Between Ploidy and Antifungal Drugs
por: Avramovska, Ognenka, et al.
Publicado: (2019)

Response to “Time of the Day and Magnitude of the Effect of a Drug on the QTc Interval”
por: Kervezee, L, et al.
Publicado: (2017)

Transporter-Mediated Drug–Drug Interactions with Oral Antidiabetic Drugs
por: Klatt, Sabine, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_oanj8ir9tf8grptl1h69hcu5h4